SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: November 27, 1996
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer
Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE>
Item 5. OTHER EVENTS
On November 27, 1996, the Company announced that it had
reacquired the from Bristol-Myers Squibb Company the rights
to manufacture, market and sell n-docosanol 10% cream (LIDAKOL(R))
for the treatment of oral herpes and all other therapeutic
indications in China, South and Central America, Australia and
India, and portions of Asia.
Bristol-Myers Squibb retains exclusive rights to manufacture,
market and sell LIDAKOL as a topical treatment for oral herpes
in the United States, Mexico and Canada. LIDAK retains all
rights to LIDAKOL in these countries for treatment of genital
herpes and other potential topical and systemic uses, for which
Bristol-Myers Squibb retains the right-of-first offer.
Marketing rights to topical LIDAKOL are currently held in
Europe, Africa and the Middle East by Yamanouchi Europe, B.V.;
in Japan by Grelan Pharmaceuticals Co., Ltd.; in Korea by
Boryung Pharmaceutical Co., Ltd.; and in Isreal by CTS Chemical
Industries, Ltd.
SIGNATURES
Pursuant to the requirements of the Securities and
Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.
LIDAK PHARMACEUTICALS
Date: December 3, 1996 By:/s/David H. Katz
-----------------------
President and Chief Executive
Officer
